Mammalian target of rapamycin integrates diverse inputs to guide the outcome of antigen recognition in T cells

Journal of Immunology

Volumn 188, Issue 10, 2012, Pages 4721-4729

  Waickman, Adam T ^a   Powell, Jonathan D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CHEMOKINE; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 7 RECEPTOR; LYSOPHOSPHOLIPID; MAMMALIAN TARGET OF RAPAMYCIN;

ANTIGEN RECOGNITION; APOPTOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MIGRATION; CYTOKINE PRODUCTION; GLYCOLYSIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; SHORT SURVEY; T LYMPHOCYTE;

ANIMALS; ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; TOR SERINE-THREONINE KINASES;

EID: 84861157343     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1103143     Document Type: Short Survey

References (124)

1. O'Garra, A. 1998. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8: 275-283. (Pubitemid 28188888)
2. Soroosh, P., and T. A. Doherty. 2009. Th9 and allergic disease. Immunology 127: 450-458.
3. Harrington, L. E., P. R. Mangan, and C. T. Weaver. 2006. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr. Opin. Immunol. 18: 349-356.
4. Crotty, S. 2011. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29: 621-663.
5. Rudensky, A. Y. 2011. Regulatory T cells and Foxp3. Immunol. Rev. 241: 260-268.
6. Curtsinger, J. M., and M. F. Mescher. 2010. Inflammatory cytokines as a third signal for T cell activation. Curr. Opin. Immunol. 22: 333-340.
7. Thomson, A. W., H. R. Turnquist, and G. Raimondi. 2009. Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol. 9: 324-337.
8. Powell, J. D., K. N. Pollizzi, E. B. Heikamp, and M. R. Horton. 2012. Regulation of Immune Responses by mTOR. Annu. Rev. Immunol. 30: 39-68.
9. Brown, E. J., M. W. Albers, T. B. Shin, K. Ichikawa, C. T. Keith, W. S. Lane, and S. L. Schreiber. 1994. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369: 756-758.
10. Esposito, M., F. Ruffini, M. Bellone, N. Gagliani, M. Battaglia, G. Martino, and R. Furlan. 2010. Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation. J. Neuroimmunol. 220: 52-63.
11. Campistol, J. M., P. Cockwell, F. Diekmann, D. Donati, L. Guirado, G. Herlenius, D. Mousa, J. Pratschke, and J. C. San Millán. 2009. Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation. Transpl. Int. 22: 681-687.
12. Cutler, C., and J. H. Antin. 2004. Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation. Bone Marrow Transplant. 34: 471-476. (Pubitemid 39264035)
13. Laplante, M., and D. M. Sabatini. 2009. mTOR signaling at a glance. J. Cell Sci. 122: 3589-3594.
14. Yamagata, K., L. K. Sanders, W. E. Kaufmann, W. Yee, C. A. Barnes, D. Nathans, and P. F. Worley. 1994. rheb, a growth factor- and synaptic activity-regulated gene, encodes a novel Ras-related protein. J. Biol. Chem. 269: 16333-16339. (Pubitemid 24209331)
15. Zhang, Y., X. Gao, L. J. Saucedo, B. Ru, B. A. Edgar, and D. Pan. 2003. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol. 5: 578-581. (Pubitemid 36781094)
16. Inoki, K., Y. Li, T. Zhu, J. Wu, and K. L. Guan. 2002. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4: 648-657. (Pubitemid 34993700)
17. Macintyre, A. N., D. Finlay, G. Preston, L. V. Sinclair, C. M. Waugh, P. Tamas, C. Feijoo, K. Okkenhaug, and D. A. Cantrell. 2011. Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. Immunity 34: 224-236.
18. Vander Haar, E., S. I. Lee, S. Bandhakavi, T. J. Griffin, and D. H. Kim. 2007. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell Biol. 9: 316-323. (Pubitemid 46344611)
19. Beugnet, A., A. R. Tee, P. M. Taylor, and C. G. Proud. 2003. Regulation of targets of mTOR (mammalian target of rapamycin) signalling by intracellular amino acid availability. Biochem. J. 372: 555-566. (Pubitemid 36723901)
20. Cunningham, J. T., J. T. Rodgers, D. H. Arlow, F. Vazquez, V. K. Mootha, and P. Puigserver. 2007. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 450: 736-740. (Pubitemid 350207689)
21. Yu, L., C. K. McPhee, L. Zheng, G. A. Mardones, Y. Rong, J. Peng, N. Mi, Y. Zhao, Z. Liu, F. Wan, et al. 2010. Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature 465: 942-946.
22. Yecies, J. L., and B. D. Manning. 2011. Transcriptional control of cellular metabolism by mTOR signaling. Cancer Res. 71: 2815-2820.
23. Sengupta, S., T. R. Peterson, and D. M. Sabatini. 2010. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol. Cell 40: 310-322.
24. Zinzalla, V., D. Stracka, W. Oppliger, and M. N. Hall. 2011. Activation of mTORC2 by association with the ribosome. Cell 144: 757-768.
25. Chen, C. H., T. Shaikenov, T. R. Peterson, R. Aimbetov, A. K. Bissenbaev, S. W. Lee, J. Wu, H. K. Lin, and D. Sarbassov. 2011. ER stress inhibits mTORC2 and Akt signaling through GSK-3β-mediated phosphorylation of rictor. Sci. Signal. 4: ra10.
26. García-Martínez, J. M., and D. R. Alessi. 2008. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem. J. 416: 375-385.
27. Guertin, D. A., D. M. Stevens, C. C. Thoreen, A. A. Burds, N. Y. Kalaany, J. Moffat, M. Brown, K. J. Fitzgerald, and D. M. Sabatini. 2006. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell 11: 859-871. (Pubitemid 44804279)
28. Delgoffe, G. M., K. N. Pollizzi, A. T. Waickman, E. Heikamp, D. J. Meyers, M. R. Horton, B. Xiao, P. F. Worley, and J. D. Powell. 2011. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 12: 295-303.
29. Lee, K., P. Gudapati, S. Dragovic, C. Spencer, S. Joyce, N. Killeen, M. A. Magnuson, and M. Boothby. 2010. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 32: 743-753.
30. Delgoffe, G. M., T. P. Kole, Y. Zheng, P. E. Zarek, K. L. Matthews, B. Xiao, P. F. Worley, S. C. Kozma, and J. D. Powell. 2009. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30: 832-844.
31. Kang, J., S. J. Huddleston, J. M. Fraser, and A. Khoruts. 2008. De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR. J. Leukoc. Biol. 83: 1230-1239. (Pubitemid 351960355)
32. Haxhinasto, S., D. Mathis, and C. Benoist. 2008. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J. Exp. Med. 205: 565-574. (Pubitemid 351439304)
33. Zeiser, R., D. B. Leveson-Gower, E. A. Zambricki, N. Kambham, A. Beilhack, J. Loh, J. Z. Hou, and R. S. Negrin. 2008. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 111: 453-462.
34. Sauer, S., L. Bruno, A. Hertweck, D. Finlay, M. Leleu, M. Spivakov, Z. A. Knight, B. S. Cobb, D. Cantrell, E. O'Connor, et al. 2008. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc. Natl. Acad. Sci. USA 105: 7797-7802. (Pubitemid 351872718)
35. Gabryšová, L., J. R. Christensen, X. Wu, A. Kissenpfennig, B. Malissen, and A. O'Garra. 2011. Integrated T-cell receptor and costimulatory signals determine TGF-β-dependent differentiation and maintenance of Foxp3+ regulatory T cells. Eur. J. Immunol. 41: 1242-1248.
36. Sarbassov, D. D., S. M. Ali, S. Sengupta, J. H. Sheen, P. P. Hsu, A. F. Bagley, A. L. Markhard, and D. M. Sabatini. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22: 159-168.
37. Benjamin, D., M. Colombi, C. Moroni, and M. N. Hall. 2011. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat. Rev. Drug Discov. 10: 868-880.
38. Düvel, K., J. L. Yecies, S. Menon, P. Raman, A. I. Lipovsky, A. L. Souza, E. Triantafellow, Q. Ma, R. Gorski, S. Cleaver, et al. 2010. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39: 171-183.
39. Jones, R. G., and C. B. Thompson. 2007. Revving the engine: signal transduction fuels T cell activation. Immunity 27: 173-178. (Pubitemid 47284920)
40. Fox, C. J., P. S. Hammerman, and C. B. Thompson. 2005. Fuel feeds function: energy metabolism and the T-cell response. Nat. Rev. Immunol. 5: 844-852. (Pubitemid 41581666)
41. Pearce, E. L. 2010. Metabolism in T cell activation and differentiation. Curr. Opin. Immunol. 22: 314-320.
42. Salmond, R. J., J. Emery, K. Okkenhaug, and R. Zamoyska. 2009. MAPK, phosphatidylinositol 3-kinase, and mammalian target of rapamycin pathways converge at the level of ribosomal protein S6 phosphorylation to control metabolic signaling in CD8 T cells. J. Immunol. 183: 7388-7397.
43. Araki, K., A. P. Turner, V. O. Shaffer, S. Gangappa, S. A. Keller, M. F. Bachmann, C. P. Larsen, and R. Ahmed. 2009. mTOR regulates memory CD8 T-cell differentiation. Nature 460: 108-112.
44. He, S., K. Kato, J. Jiang, D. R. Wahl, S. Mineishi, E. M. Fisher, D. M. Murasko, G. D. Glick, and Y. Zhang. 2011. Characterization of the metabolic phenotype of rapamycin-treated CD8+ T cells with augmented ability to generate long-lasting memory cells. PLoS ONE 6: e20107.
45. Rao, R. R., Q. Li, K. Odunsi, and P. A. Shrikant. 2010. The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity 32: 67-78.
46. Li, Q., R. R. Rao, K. Araki, K. Pollizzi, K. Odunsi, J. D. Powell, and P. A. Shrikant. 2011. A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. Immunity 34: 541-553.
47. Pearce, E. L., M. C. Walsh, P. J. Cejas, G. M. Harms, H. Shen, L. S. Wang, R. G. Jones, and Y. Choi. 2009. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460: 103-107.
48. Finlay, D., and D. Cantrell. 2010. Phosphoinositide 3-kinase and the mammalian target of rapamycin pathways control T cell migration. Ann. N. Y. Acad. Sci. 1183: 149-157.
49. Fabre, S., F. Carrette, J. Chen, V. Lang, M. Semichon, C. Denoyelle, V. Lazar, N. Cagnard, A. Dubart-Kupperschmitt, M. Mangeney, et al. 2008. FOXO1 regulates L-Selectin and a network of human T cell homing molecules downstream of phosphatidylinositol 3-kinase. J. Immunol. 181: 2980-2989.
50. Kerdiles, Y. M., D. R. Beisner, R. Tinoco, A. S. Dejean, D. H. Castrillon, R. A. DePinho, and S. M. Hedrick. 2009. Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nat. Immunol. 10: 176-184.
51. Finlay, D., and D. A. Cantrell. 2011. Metabolism, migration and memory in cytotoxic T cells. Nat. Rev. Immunol. 11: 109-117.
52. Sinclair, L. V., D. Finlay, C. Feijoo, G. H. Cornish, A. Gray, A. Ager, K. Okkenhaug, T. J. Hagenbeek, H. Spits, and D. A. Cantrell. 2008. Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat. Immunol. 9: 513-521. (Pubitemid 351560520)
53. Carlson, C. M., B. T. Endrizzi, J. Wu, X. Ding, M. A. Weinreich, E. R. Walsh, M. A. Wani, J. B. Lingrel, K. A. Hogquist, and S. C. Jameson. 2006. Kruppel-like factor 2 regulates thymocyte and T-cell migration. Nature 442: 299-302. (Pubitemid 44114904)
54. Matloubian, M., C. G. Lo, G. Cinamon, M. J. Lesneski, Y. Xu, V. Brinkmann, M. L. Allende, R. L. Proia, and J. G. Cyster. 2004. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427: 355-360. (Pubitemid 38133663)
55. Michalek, R. D., V. A. Gerriets, S. R. Jacobs, A. N. Macintyre, N. J. MacIver, E. F. Mason, S. A. Sullivan, A. G. Nichols, and J. C. Rathmell. 2011. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J. Immunol. 186: 3299-3303.
56. Kawai, K., and P. S. Ohashi. 1995. Immunological function of a defined T-cell population tolerized to low-affinity self antigens. Nature 374: 68-69.
57. Badou, A., M. Savignac, M. Moreau, C. Leclerc, G. Foucras, G. Cassar, P. Paulet, D. Lagrange, P. Druet, J. C. Guéry, and L. Pelletier. 2001. Weak TCR stimulation induces a calcium signal that triggers IL-4 synthesis, stronger TCR stimulation induces MAP kinases that control IFN-gamma production. Eur. J. Immunol. 31: 2487-2496. (Pubitemid 32785368)
58. Gottschalk, R. A., E. Corse, and J. P. Allison. 2010. TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo. J. Exp. Med. 207: 1701-1711.
59. Exley, M., L. Varticovski, M. Peter, J. Sancho, and C. Terhorst. 1994. Association of phosphatidylinositol 3-kinase with a specific sequence of the T cell receptor zeta chain is dependent on T cell activation. J. Biol. Chem. 269: 15140-15146. (Pubitemid 24198359)
60. Jonuleit, H., E. Schmitt, G. Schuler, J. Knop, and A. H. Enk. 2000. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192: 1213-1222.
61. Katzman, S. D., W. E. O'Gorman, A. V. Villarino, E. Gallo, R. S. Friedman, M. F. Krummel, G. P. Nolan, and A. K. Abbas. 2010. Duration of antigen receptor signaling determines T-cell tolerance or activation. Proc. Natl. Acad. Sci. USA 107: 18085-18090.
62. Verweij, C. L., M. Geerts, and L. A. Aarden. 1991. Activation of interleukin-2 gene transcription via the T-cell surface molecule CD28 is mediated through an NF-kB-like response element. J. Biol. Chem. 266: 14179-14182. (Pubitemid 21907480)
63. Harada, Y., M. Tokushima, Y. Matsumoto, S. Ogawa, M. Otsuka, K. Hayashi, B. D. Weiss, C. H. June, and R. Abe. 2001. Critical requirement for the membrane-proximal cytosolic tyrosine residue for CD28-mediated costimulation in vivo. J. Immunol. 166: 3797-3803. (Pubitemid 32224904)
64. Kane, L. P., P. G. Andres, K. C. Howland, A. K. Abbas, and A. Weiss. 2001. Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-gamma but not TH2 cytokines. Nat. Immunol. 2: 37-44. (Pubitemid 33704951)
65. Colombetti, S., V. Basso, D. L. Mueller, and A. Mondino. 2006. Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target of rapamycin. J. Immunol. 176: 2730-2738.
66. Boonen, G. J., A. M. van Dijk, L. F. Verdonck, R. A. van Lier, G. Rijksen, and R. H. Medema. 1999. CD28 induces cell cycle progression by IL-2-independent down-regulation of p27kip1 expression in human peripheral T lymphocytes. Eur. J. Immunol. 29: 789-798. (Pubitemid 29119058)
67. Frauwirth, K. A., J. L. Riley, M. H. Harris, R. V. Parry, J. C. Rathmell, D. R. Plas, R. L. Elstrom, C. H. June, and C. B. Thompson. 2002. The CD28 signaling pathway regulates glucose metabolism. Immunity 16: 769-777. (Pubitemid 34786476)
68. Fos, C., A. Salles, V. Lang, F. Carrette, S. Audebert, S. Pastor, M. Ghiotto, D. Olive, G. Bismuth, and J. A. Nunès. 2008. ICOS ligation recruits the p50alpha PI3K regulatory subunit to the immunological synapse. J. Immunol. 181: 1969-1977.
69. Gramaglia, I., A. D. Weinberg, M. Lemon, and M. Croft. 1998. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 161: 6510-6517. (Pubitemid 28562188)
70. Redmond, W. L., C. E. Ruby, and A. D. Weinberg. 2009. The role of OX40-mediated co-stimulation in T-cell activation and survival. Crit. Rev. Immunol. 29: 187-201.
71. Xiao, X., W. Gong, G. Demirci, W. Liu, S. Spoerl, X. Chu, D. K. Bishop, L. A. Turka, and X. C. Li. 2012. New insights on OX40 in the control of T cell immunity and immune tolerance in vivo. J. Immunol. 188: 892-901.
72. So, T., H. Choi, and M. Croft. 2011. OX40 complexes with phosphoinositide 3-kinase and protein kinase B (PKB) to augment TCR-dependent PKB signaling. J. Immunol. 186: 3547-3555.
73. Ruby, C. E., W. L. Redmond, D. Haley, and A. D. Weinberg. 2007. Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses. Eur. J. Immunol. 37: 157-166. (Pubitemid 46128796)
74. Parry, R. V., J. M. Chemnitz, K. A. Frauwirth, A. R. Lanfranco, I. Braunstein, S. V. Kobayashi, P. S. Linsley, C. B. Thompson, and J. L. Riley. 2005. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25: 9543-9553. (Pubitemid 41507854)
75. Chuang, E., T. S. Fisher, R. W. Morgan, M. D. Robbins, J. M. Duerr, M. G. Vander Heiden, J. P. Gardner, J. E. Hambor, M. J. Neveu, and C. B. Thompson. 2000. The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A. Immunity 13: 313-322.
76. Schneider, H., E. Valk, R. Leung, and C. E. Rudd. 2008. CTLA-4 activation of phosphatidylinositol 3-kinase (PI 3-K) and protein kinase B (PKB/AKT) sustains T-cell anergy without cell death. PLoS ONE 3: e3842.
77. Riley, J. L. 2009. PD-1 signaling in primary T cells. Immunol. Rev. 229: 114-125.
78. Vibhakar, R., G. Juan, F. Traganos, Z. Darzynkiewicz, and L. R. Finger. 1997. Activation-induced expression of human programmed death-1 gene in T-lymphocytes. Exp. Cell Res. 232: 25-28. (Pubitemid 27172215)
79. Chemnitz, J. M., R. V. Parry, K. E. Nichols, C. H. June, and J. L. Riley. 2004. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173: 945-954. (Pubitemid 38924267)
80. Sheppard, K. A., L. J. Fitz, J. M. Lee, C. Benander, J. A. George, J. Wooters, Y. Qiu, J. M. Jussif, L. L. Carter, C. R. Wood, and D. Chaudhary. 2004. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 574: 37-41. (Pubitemid 39200891)
81. Francisco, L. M., V. H. Salinas, K. E. Brown, V. K. Vanguri, G. J. Freeman, V. K. Kuchroo, and A. H. Sharpe. 2009. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206: 3015-3029.
82. Chow, L. M., and S. J. Baker. 2006. PTEN function in normal and neoplastic growth. Cancer Lett. 241: 184-196. (Pubitemid 44163047)
83. Abraham, R. T., and G. J. Wiederrecht. 1996. Immunopharmacology of rapamycin. Annu. Rev. Immunol. 14: 483-510. (Pubitemid 26130192)
84. Allen, A., Y. Zheng, L. Gardner, M. Safford, M. R. Horton, and J. D. Powell. 2004. The novel cyclophilin binding compound, sanglifehrin A, disassociates G1 cell cycle arrest from tolerance induction. J. Immunol. 172: 4797-4803. (Pubitemid 38456401)
85. Powell, J. D., C. G. Lerner, and R. H. Schwartz. 1999. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J. Immunol. 162: 2775-2784. (Pubitemid 29309302)
86. Vanasek, T. L., A. Khoruts, T. Zell, and D. L. Mueller. 2001. Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy: enhanced cell cycle progression promotes recall antigen responsiveness. J. Immunol. 167: 5636-5644. (Pubitemid 33062753)
87. Duré, M., and F. Macian. 2009. IL-2 signaling prevents T cell anergy by inhibiting the expression of anergy-inducing genes. Mol. Immunol. 46: 999-1006.
88. Stephenson, L. M., D. S. Park, A. L. Mora, S. Goenka, and M. Boothby. 2005. Sequence motifs in IL-4R alpha mediating cell-cycle progression of primary lymphocytes. J. Immunol. 175: 5178-5185. (Pubitemid 41456402)
89. Barata, J. T., A. Silva, J. G. Brandao, L. M. Nadler, A. A. Cardoso, and V. A. Boussiotis. 2004. Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J. Exp. Med. 200: 659-669. (Pubitemid 39258314)
90. Rathmell, J. C., E. A. Farkash, W. Gao, and C. B. Thompson. 2001. IL-7 enhances the survival and maintains the size of naive T cells. J. Immunol. 167: 6869-6876. (Pubitemid 33144179)
91. Gulen, M. F., Z. Kang, K. Bulek, W. Youzhong, T. W. Kim, Y. Chen, C. Z. Altuntas, K. Sass Bak-Jensen, M. J. McGeachy, J. S. Do, et al. 2010. The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation. Immunity 32: 54-66.
92. Uddin, S., L. Yenush, X. J. Sun, M. E. Sweet, M. F. White, and L. C. Platanias. 1995. Interferon-alpha engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 39-kinase. J. Biol. Chem. 270: 15938-15941.
93. Platanias, L. C., S. Uddin, A. Yetter, X. J. Sun, and M. F. White. 1996. The type I interferon receptor mediates tyrosine phosphorylation of insulin receptor substrate 2. J. Biol. Chem. 271: 278-282. (Pubitemid 26026590)
94. Navarro, A., B. Anand-Apte, Y. Tanabe, G. Feldman, and A. C. Larner. 2003. A PI-3 kinase-dependent, Stat1-independent signaling pathway regulates interferon-stimulated monocyte adhesion. J. Leukoc. Biol. 73: 540-545. (Pubitemid 38040100)
95. Curnock, A. P., and S. G. Ward. 2003. Development and characterisation of tetracycline-regulated phosphoinositide 3-kinase mutants: assessing the role of multiple phosphoinositide 3-kinases in chemokine signaling. J. Immunol. Methods 273: 29-41. (Pubitemid 36078460)
96. Sasaki, T., J. Irie-Sasaki, R. G. Jones, A. J. Oliveira-dos-Santos, W. L. Stanford, B. Bolon, A. Wakeham, A. Itie, D. Bouchard, I. Kozieradzki, et al. 2000. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 287: 1040-1046.
97. Sakakibara, K., B. Liu, S. Hollenbeck, and K. C. Kent. 2005. Rapamycin inhibits fibronectin-induced migration of the human arterial smooth muscle line (E47) through the mammalian target of rapamycin. Am. J. Physiol. Heart Circ. Physiol. 288: H2861-H2868. (Pubitemid 40720668)
98. Gomez-Cambronero, J. 2003. Rapamycin inhibits GM-CSF-induced neutrophil migration. FEBS Lett. 550: 94-100. (Pubitemid 37281364)
99. Munk, R., P. Ghosh, M. C. Ghosh, T. Saito, M. Xu, A. Carter, F. Indig, D. D. Taub, and D. L. Longo. 2011. Involvement of mTOR in CXCL12 mediated T cell signaling and migration. PLoS ONE 6: e24667.
100. Murooka, T. T., R. Rahbar, L. C. Platanias, and E. N. Fish. 2008. CCL5-mediated T-cell chemotaxis involves the initiation of mRNA translation through mTOR/4E-BP1. Blood 111: 4892-4901.
101. Myers, M. G., Jr. 2004. Leptin receptor signaling and the regulation of mammalian physiology. Recent Prog. Horm. Res. 59: 287-304.
102. Kellerer, M., M. Koch, E. Metzinger, J. Mushack, E. Capp, and H. U. Häring. 1997. Leptin activates PI-3 kinase in C2C12 myotubes via janus kinase-2 (JAK-2) and insulin receptor substrate-2 (IRS-2) dependent pathways. Diabetologia 40: 1358-1362. (Pubitemid 27469678)
103. Galgani, M., C. Procaccini, V. De Rosa, F. Carbone, P. Chieffi, A. La Cava, and G. Matarese. 2010. Leptin modulates the survival of autoreactive CD4+ T cells through the nutrient/energy-sensing mammalian target of rapamycin signaling pathway. J. Immunol. 185: 7474-7479.
104. Procaccini, C., V. De Rosa, M. Galgani, L. Abanni, G. Calì, A. Porcellini, F. Carbone, S. Fontana, T. L. Horvath, A. La Cava, and G. Matarese. 2010. An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. Immunity 33: 929-941.
105. Liu, G., S. Burns, G. Huang, K. Boyd, R. L. Proia, R. A. Flavell, and H. Chi. 2009. The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR. Nat. Immunol. 10: 769-777.
106. Liu, G., K. Yang, S. Burns, S. Shrestha, and H. Chi. 2010. The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and T(reg) cells. Nat. Immunol. 11: 1047-1056.
107. Bai, A., H. Hu, M. Yeung, and J. Chen. 2007. Kruppel-like factor 2 controls T cell trafficking by activating L-selectin (CD62L) and sphingosine-1-phosphate receptor 1 transcription. J. Immunol. 178: 7632-7639. (Pubitemid 46898033)
108. Gwinn, D. M., D. B. Shackelford, D. F. Egan, M. M. Mihaylova, A. Mery, D. S. Vasquez, B. E. Turk, and R. J. Shaw. 2008. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30: 214-226. (Pubitemid 351626684)
109. Zheng, Y., G. M. Delgoffe, C. F. Meyer, W. Chan, and J. D. Powell. 2009. Anergic T cells are metabolically anergic. J. Immunol. 183: 6095-6101.
110. Jhun, B. S., Y. T. Oh, J. Y. Lee, Y. Kong, K. S. Yoon, S. S. Kim, H. H. Baik, J. Ha, and I. Kang. 2005. AICAR suppresses IL-2 expression through inhibition of GSK-3 phosphorylation and NF-AT activation in Jurkat T cells. Biochem. Biophys. Res. Commun. 332: 339-346. (Pubitemid 40724983)
111. Nath, N., S. Giri, R. Prasad, M. L. Salem, A. K. Singh, and I. Singh. 2005. 5-aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis. J. Immunol. 175: 566-574. (Pubitemid 40884363)
112. Jiang, W., Z. Zhu, and H. J. Thompson. 2008. Modulation of the activities of AMP-activated protein kinase, protein kinase B, and mammalian target of rapamycin by limiting energy availability with 2-deoxyglucose. Mol. Carcinog. 47: 616-628.
113. Cham, C. M., and T. F. Gajewski. 2005. Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells. J. Immunol. 174: 4670-4677.
114. Inoki, K., H. Ouyang, T. Zhu, C. Lindvall, Y. Wang, X. Zhang, Q. Yang, C. Bennett, Y. Harada, K. Stankunas, et al. 2006. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126: 955-968. (Pubitemid 44310775)
115. Brugarolas, J., K. Lei, R. L. Hurley, B. D. Manning, J. H. Reiling, E. Hafen, L. A. Witters, L. W. Ellisen, and W. G. Kaelin, Jr. 2004. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 18: 2893-2904. (Pubitemid 39602308)
116. Sofer, A., K. Lei, C. M. Johannessen, and L. W. Ellisen. 2005. Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol. Cell. Biol. 25: 5834-5845. (Pubitemid 40946541)
117. DeYoung, M. P., P. Horak, A. Sofer, D. Sgroi, and L. W. Ellisen. 2008. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 22: 239-251.
118. Hudson, C. C., M. Liu, G. G. Chiang, D. M. Otterness, D. C. Loomis, F. Kaper, A. J. Giaccia, and R. T. Abraham. 2002. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 22: 7004-7014.
119. Nakamura, H., Y. Makino, K. Okamoto, L. Poellinger, K. Ohnuma, C. Morimoto, and H. Tanaka. 2005. TCR engagement increases hypoxia-inducible factor-1 alpha protein synthesis via rapamycin-sensitive pathway under hypoxic conditions in human peripheral T cells. J. Immunol. 174: 7592-7599. (Pubitemid 40806263)
120. Dang, E. V., J. Barbi, H. Y. Yang, D. Jinasena, H. Yu, Y. Zheng, Z. Bordman, J. Fu, Y. Kim, H. R. Yen, et al. 2011. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 146: 772-784.
121. Shi, L. Z., R. Wang, G. Huang, P. Vogel, G. Neale, D. R. Green, and H. Chi. 2011. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 208: 1367-1376.
122. Sancak, Y., T. R. Peterson, Y. D. Shaul, R. A. Lindquist, C. C. Thoreen, L. Bar-Peled, and D. M. Sabatini. 2008. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320: 1496-1501. (Pubitemid 351929429)
123. Cobbold, S. P., E. Adams, C. A. Farquhar, K. F. Nolan, D. Howie, K. O. Lui, P. J. Fairchild, A. L. Mellor, D. Ron, and H. Waldmann. 2009. Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc. Natl. Acad. Sci. USA 106: 12055-12060.
124. Hidayat, S., K. Yoshino, C. Tokunaga, K. Hara, M. Matsuo, and K. Yonezawa. 2003. Inhibition of amino acid-mTOR signaling by a leucine derivative induces G1 arrest in Jurkat cells. Biochem. Biophys. Res. Commun. 301: 417-423. (Pubitemid 36279255)